20 results
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
arrangements would be in the best interests of Galapagos and its shareholders, not seeking to pay more than appropriate to recruit, engage and retain
6-K
EX-99.1
GLPG
Galapagos NV
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
, with the aim to recruit the first patients around year-end
Corporate update
Received various transparency notifications from FMR LLC, indicating that its … following the PRAC Article 20 recommendation issued on 28 October 2022.
We aim to recruit the first patients in a Phase 2 study of our TYK2 inhibitor
6-K
EX-99.2
GLPG
Galapagos NV
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
) in dermatomyositis, with the aim to recruit the first patients around year-end Corporate update Received various transparency notifications from FMR … on 28 October 2022. We aim to recruit the first patients in a Phase 2 study of our TYK2 inhibitor product candidate, GLPG3667, in dermatomyositis
6-K
EX-99.3
qk76657v5
11 May 21
Current report (foreign)
2:10pm
6-K
EX-99.2
imjrz 0it1
6 Aug 20
Galapagos reports solid H1 2020 progress
4:01pm
6-K
EX-99.2
25qgz2 qy
26 Apr 19
Galapagos reports on historic first quarter 2019
4:06pm
6-K
EX-99.1
2ko0 3a1w9k
26 Apr 19
Galapagos reports on historic first quarter 2019
4:06pm
6-K
EX-99.1
wu4jw472o0g
7 Jan 19
Current report (foreign)
7:29am
6-K
EX-99.1
0t8uab7
28 Nov 18
Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis
6:00am
6-K
EX-99.1
fvfix cxtmfxst
24 Sep 18
Galapagos reports initiation of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in osteoarthritis patients
6:05am
6-K
EX-99.1
xra4p2tnd2h3hua9mj62
27 Jun 18
Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis patients
6:01am
6-K
EX-99
zsa3f06 23p4
4 Apr 17
Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib
12:00am
20-F
7g1kfsk tfq
25 Mar 16
Annual report (foreign)
12:00am
- Prev
- 1
- Next